Le Lézard
Classified in: Health, Science and technology
Subject: FDA

FDA Clears ORTHOtm Sera ID-MTS for Use on the ORTHO VISION® Analyzer


RARITAN, N.J., Oct. 18, 2019 /PRNewswire/ -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced that ORTHOtm Sera, a suite of extended antigen phenotyping, has been cleared by the U.S. Food and Drug Administration for use on the ORTHO VISION® Analyzer.

logo

During pre-transfusion testing, lab professionals routinely encounter complex patient samples that require extended antigen typing. These patients have developed atypical antibodies to blood group antigens and require additional testing to find compatible blood.1 ORTHO Sera's extended phenotype testing covers more than 99 percent of the most commonly tested blood group antigens, providing support for patients with unexpected antibodies.

"It is critically important for lab professionals to deliver the right results for complex and chronically transfused patients," said Bob Stowers, head of Ortho's transfusion medicine product portfolio. "That's why we are excited to be the first to offer automated extended phenotype testing, saving time for the lab professional and giving skilled staff the ability to focus on other critical tasks in the lab, as well as to increase the lab's ability to standardize testing."

Allowing virtually all testing to be done on one platform, ORTHO Sera expands the testing menu on the ORTHO VISION Analyzer, driving greater value and efficiency for customers and delivering results in a maximum of 20 minutes. With end-to-end full automation on the ORTHO VISION Analyzer, ORTHO Sera minimizes the potential for human error, improving safety, and provides consistent, reliable results while freeing up lab professionals to focus on value-added tasks.

ORTHO Sera's antisera additive approach allows extended phenotyping to be personalized according to patient needs, which reduces waste and enhances efficiency. Decreased hands-on manipulation of tests helps to eliminate time-consuming, non-value-added activities and potential for error. The 13 ORTHO Sera reagents available in the U.S. on the ORTHO VISION Analyzer include Anti-Fya, Anti-Fyb, Anti-Jka, Anti-Jkb, Anti-S, Anti-s, Anti-K, Anti-D (IAT), Anti-D (DVI), Anti-P1, Anti-Lea, Anti-Leb and Anti-N.

For more information, follow Ortho on LinkedIn, Twitter, Facebook and Instagram.

About Ortho Clinical Diagnostics
Ortho Clinical Diagnostics is a global leader of in vitro diagnostics serving the clinical laboratory and immunohematology communities. Across hospitals, hospital networks, blood banks and labs in more than 125 countries and territories, Ortho's high-quality products and services enable health care professionals to make better-informed treatment decisions. For the immunohematology community, Ortho's blood typing products help ensure every patient receives blood that is safe, the right type and the right unit. Ortho brings sophisticated testing technologies, automation, information management and interpretation tools to clinical laboratories around the world to help them run more efficiently and effectively and improve patient care. Ortho's purpose is to improve and save lives with diagnostics, and it does that by reimagining what's possible. This is what has defined Ortho for more than 75 years, and it's what drives Ortho forward. For more information, visit www.orthoclinicaldiagnostics.com.

© Ortho Clinical Diagnostics 2019

PR-05281

1 Hamilton JR_Common and Frequently Encountered Antibodies_Transfusion and Apheresis Science 2009_ 40_189_194

SOURCE Ortho Clinical Diagnostics


These press releases may also interest you

at 19:10
dynaCERT Inc. (FRA: DMJ) ("dynaCERT" or the "Company") announces that 6,938,677 warrants (approximately 96.5 %) have been exercised for gross proceeds of approximately $ 2,428,537 to the Company pursuant to its Press Release dated November 9, 2019...

at 19:00
HaasOnline has announced the first official partnership with the Bitpanda Global Exchange as a complete trade automation solutions partner. Since their initial exchange offering which raised ?43.6 million, Bitpanda has been ascending the exchange...

at 18:58
CenturyLink, Inc. (the "Company" or "CenturyLink") announced that it has agreed to sell $1.25 billion aggregate principal amount of its newly-issued unsecured 5.125% Senior Notes due 2026 (the "2026 Notes") pursuant to the private offering announced...

at 18:30
Global technology leader OMRON Corporation will return to the Consumer Electronics Show (CES) in Las Vegas in January to share innovations in factory automation, healthcare, environmental and social solutions. OMRON invites CES 2020 attendees to...

at 18:20
bluebird bio, Inc. and Bristol-Myers Squibb announced updated safety and efficacy results from the ongoing Phase 1 study (CRB-402) of bb21217, an investigational BCMA-targeted chimeric antigen receptor (CAR) T cell therapy being studied in patients...

at 18:20
Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, today presented topline data from the ASCERTAIN phase 3 trial of the orally administered fixed dose combination of cedazuridine and...



News published on 18 october 2019 at 08:01 and distributed by: